{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:09:27Z","timestamp":1780805367647,"version":"3.54.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Enzyme-inducing antiepileptic drugs (EIAEDs) are among the clinically most important inducers of cytochrome P450 (CYP) 3A4, but there is limited evidence regarding the comparative potency of each EIAED in raising CYP3A4 activity. The aim of this study was to estimate CYP3A4-inductive potency of EIAEDs by comparing CYP3A4 activity in patients treated with carbamazepine, phenobarbital, or phenytoin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Residual serum samples from patients treated with EIAEDs or levetiracetam were collected from a therapeutic drug monitoring service for analysis of 4\u03b2-hydroxycholesterol (4\u03b2OHC), which is an indicator of CYP3A4 activity. The samples were collected between January and September 2016 at Diakonhjemmet Hospital, Oslo, Norway. Concentration of 4\u03b2OHC, EIAEDs, and levetiracetam was measured by ultra-performance liquid chromatography tandem mass spectrometry. Kruskal\u2013Wallis and Mann\u2013Whitney tests were used for comparison of 4\u03b2OHC levels between the subgroups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 4\u03b2OHC measurements for 343 and 339 patients treated with EIAEDs and levetiracetam, respectively, were included in the study. Compared with levetiracetam-treated patients, the median 4\u03b2OHC concentration was 3.3-fold, 5.8-fold, and 6.9-fold higher in patients using phenobarbital, phenytoin, or carbamazepine, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). Phenytoin users (n = 65) and carbamazepine users (n = 225) had 1.8- and 2.1-fold higher median 4\u03b2OHC concentration than phenobarbital users (n = 28), respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> \u2264 0.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study shows that phenytoin and carbamazepine have approximately twice the CYP3A4-inducing potency of phenobarbital. The results indicate that 2-fold higher doses of CYP3A4-metabolized drugs may generally be required during concurrent treatment with phenytoin or carbamazepine compared with phenobarbital.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000518","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:39Z","timestamp":1523491239000},"page":"463-468","source":"Crossref","is-referenced-by-count":33,"title":["Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4\u03b2-Hydroxycholesterol as Biomarker"],"prefix":"10.1097","volume":"40","author":[{"given":"Kristine","family":"Hole","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit M.","family":"Wollmann","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"},{"name":"Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Haslemo","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital; and"},{"name":"Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00228-016-2178-y","article-title":"Impact of genetic and nongenetic factors on interindividual variability in 4beta-hydroxycholesterol concentration","volume":"73","author":"Hole","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1684\/epd.2014.0714","article-title":"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs","volume":"16","author":"Zaccara","year":"2014","journal-title":"Epileptic Disord."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0074-7742(06)81015-9","article-title":"Risk and predictability of drug interactions in the elderly","volume":"81","author":"Levy","year":"2007","journal-title":"Int Rev Neurobiol."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1528-1157.1996.tb00021.x","article-title":"Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin","volume":"37","author":"Backman","year":"1996","journal-title":"Epilepsia."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1984.tb02482.x","article-title":"A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients","volume":"18","author":"Perucca","year":"1984","journal-title":"Br J Clin Pharmacol."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpdd.265","article-title":"Compelling relationship of CYP3A induction to levels of the putative biomarker 4beta-hydroxycholesterol and changes in midazolam exposure","volume":"5","author":"Mangold","year":"2016","journal-title":"Clin Pharmcol Drug Dev."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bcp.12833","article-title":"4beta-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?","volume":"81","author":"Gjestad","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/bcp.13248","article-title":"The CYP3A biomarker 4\u03b2-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation","volume":"83","author":"St\u00f8rset","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2125.2005.02507.x","article-title":"Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics","volume":"61","author":"Grimm","year":"2006","journal-title":"Br J Clin Pharmacol."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-200102000-00016","article-title":"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine","volume":"21","author":"Wong","year":"2001","journal-title":"J Clin Psychopharmacol."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/bcp.13341","article-title":"4beta-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients","volume":"83","author":"Gjestad","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00007691-198909000-00008","article-title":"Relationship of intraindividual dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism","volume":"11","author":"Tomson","year":"1989","journal-title":"Ther Drug Monit."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies for antiepileptic drugs: from a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Landmark","year":"2016","journal-title":"Epileptic Disord."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1517\/17425255.2014.956081","article-title":"Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants","volume":"10","author":"Italiano","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(03)00187-5","article-title":"The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity","volume":"74","author":"Gorski","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"31534","DOI":"10.1074\/jbc.M201712200","article-title":"Metabolism of 4 beta -hydroxycholesterol in humans","volume":"277","author":"Bodin","year":"2002","journal-title":"J Biol Chem."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1365-2125.2007.03078.x","article-title":"Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy","volume":"65","author":"Wide","year":"2008","journal-title":"Br J Clin Pharmacol."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-008-0492-8","article-title":"CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels","volume":"64","author":"Josephson","year":"2008","journal-title":"Eur J Clin Pharmacol."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/tpj.2012.46","article-title":"Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients","volume":"13","author":"Habtewold","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dku286","article-title":"Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4beta-hydroxycholesterol during efavirenz treatment and efavirenz\/rifampicin co-treatment","volume":"69","author":"Ngaimisi","year":"2014","journal-title":"J Antimicrob Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:16:59Z","timestamp":1692051419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201808000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000518","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}